In CASPIAN, treatment-naïve patients with ES-SCLC received EP alone, D + EP, or D + EP and the anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab (D + T + EP) [9, 10]. Here, CTLA4 is linked to small cell lung carcinoma.